SEC Form 4 · accession 0001878313-26-000069
MAIA Biotechnology, Inc. · MAIA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean-Manasse Theagene
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001878313
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $1.44 | Jun 30, 2026 | A | 26,355 | A | Jun 30, 2026 | Jun 30, 2036 | Common Stock | 26,355 | 26,355 | D |
Explanation of responses
- F1The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.